AGEPHA Pharma’s LODOCO gets US FDA approval for cardiovascular disease
Pharmaceutical Technology
JUNE 21, 2023
It is claimed to be the first anti-inflammatory atheroprotective cardiovascular treatment to receive approval from the regulator. The regulatory approval was based on the findings obtained from a double-blind, multinational, placebo-controlled, randomised clinical trial conducted in 5,522 chronic coronary disease patients.
Let's personalize your content